DBVT · Why this verdict
Why DBV Technologies (DBVT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A risk/reward ratio of nearly 14-to-1 in your favor and 95% upside to the measured analyst price target create an exceptional geometric setup — but a quality score of 3.9, just below the 4.0 minimum floor, and free cash flow burning at roughly 15 times the annual revenue base make this a position to exit until quality clears.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The current price sits 95% below the measured analyst consensus price target of $35.33, suggesting the market is applying a steep discount to the pipeline pathway that could close materially as key milestones are reached. Price targets | Price advances to at least $27 within 12 months as pipeline milestones are met, capturing a meaningful portion of the gap to the $35.33 target. | Tripped→Stable |
| CounterAnalyst coverage is light — and the signal is explicitly dampened because of that — and the earnings history alternates between beats and misses, suggesting the path to realizing the full $35.33 target carries meaningful execution risk that the wide discount may be pricing accurately. | ||
Free cash flow is negative at a rate equal to 1,520% of revenue, meaning the company is burning cash at roughly 15 times its annual revenue base — making financial runway the single most critical constraint on any investment thesis. Quality breakdown | Cash burn rate as a share of quarterly revenue improves to less than 500% over the next four quarters, signaling that revenue is beginning to scale toward the cash consumption level. | →Stable |
| CounterEarly-stage biotechs at this commercial scale routinely carry extreme cash-burn ratios relative to their current revenue; if the primary pipeline asset advances on schedule, the burn normalizes quickly upon commercialization without requiring a structural change to the spending plan. | ||
Business quality scores 3.9 out of the required 4.0 minimum, triggering an exit recommendation regardless of how attractive the risk/reward geometry may be — position eligibility is an absolute gate, not a weighted consideration. Warnings | Quality score rises above 4.5 within four quarters as financial metrics begin to improve with commercial or pipeline progress. | ↓Deteriorating |
| CounterThe quality gap is narrow — just 0.1 points below the floor — and the asymmetry gate passes comfortably, suggesting the exit signal reflects a borderline quality assessment rather than a fundamental impairment of the business model. | ||
The risk/reward ratio is nearly 14-to-1 in your favor — 95% measured upside against 7% measured downside — one of the most favorable geometric setups available, currently blocked only by the quality floor violation. Engine gate (passed) | Once quality metrics clear the minimum threshold, the favorable asymmetry enables a position entry that could capture a substantial portion of the upside to the $35.33 target. | →Stable |
| CounterA high asymmetry ratio on a sub-threshold quality name reflects a wide analyst target gap rather than near-term catalyst visibility; without a quality improvement, the geometric opportunity may sit unrealized for multiple quarters as the company continues to burn cash. | ||
The current price sits 95% below the measured analyst consensus price target of $35.33, suggesting the market is applying a steep discount to the pipeline pathway that could close materially as key milestones are reached.
Tripped→StablePrice targets
- Expectation
- Price advances to at least $27 within 12 months as pipeline milestones are met, capturing a meaningful portion of the gap to the $35.33 target.
CounterAnalyst coverage is light — and the signal is explicitly dampened because of that — and the earnings history alternates between beats and misses, suggesting the path to realizing the full $35.33 target carries meaningful execution risk that the wide discount may be pricing accurately.
Free cash flow is negative at a rate equal to 1,520% of revenue, meaning the company is burning cash at roughly 15 times its annual revenue base — making financial runway the single most critical constraint on any investment thesis.
→StableQuality breakdown
- Expectation
- Cash burn rate as a share of quarterly revenue improves to less than 500% over the next four quarters, signaling that revenue is beginning to scale toward the cash consumption level.
CounterEarly-stage biotechs at this commercial scale routinely carry extreme cash-burn ratios relative to their current revenue; if the primary pipeline asset advances on schedule, the burn normalizes quickly upon commercialization without requiring a structural change to the spending plan.
Business quality scores 3.9 out of the required 4.0 minimum, triggering an exit recommendation regardless of how attractive the risk/reward geometry may be — position eligibility is an absolute gate, not a weighted consideration.
↓DeterioratingWarnings
- Expectation
- Quality score rises above 4.5 within four quarters as financial metrics begin to improve with commercial or pipeline progress.
CounterThe quality gap is narrow — just 0.1 points below the floor — and the asymmetry gate passes comfortably, suggesting the exit signal reflects a borderline quality assessment rather than a fundamental impairment of the business model.
The risk/reward ratio is nearly 14-to-1 in your favor — 95% measured upside against 7% measured downside — one of the most favorable geometric setups available, currently blocked only by the quality floor violation.
→StableEngine gate (passed)
- Expectation
- Once quality metrics clear the minimum threshold, the favorable asymmetry enables a position entry that could capture a substantial portion of the upside to the $35.33 target.
CounterA high asymmetry ratio on a sub-threshold quality name reflects a wide analyst target gap rather than near-term catalyst visibility; without a quality improvement, the geometric opportunity may sit unrealized for multiple quarters as the company continues to burn cash.
Per-dimension breakdown
Quality
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 9.3 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -2082% of revenue
- ▸Rule of 40: -2135 (fail)
Growth
5.0/10data confidence 50%Momentum
2.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.9 |
| OBV | 1.0 |
| MA position | 1.5 |
| Volume | 10.0 |
| vol acceleration | 1.0 |
- ▸Capitulation risk (RSI 27, below 200MA)
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope flat
- ▸Volume surge (9.5x avg) on selloff
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 249%
Insider
4.6/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.9 |
| notable moves | 3.0 |
- ▸Negligible insider selling — $1,253 (0.000% of mkt cap)
Peer rank
3.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 1.7 |
Technical
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 9.8 |
| 52w position | 0.0 |
Risk (lower is worse)
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.7 |
| days to cover | 5.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| debt equity | 9.8 |
- ▸Elevated put/call: 130.00
- ▸High IV: 362%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 6.8 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.9<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
10.6%
Sizing output
AVOID
SetupOversold Bounce — Oversold RSI 27, near Bollinger lower, volume surge
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -55% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.9<4.5 outcome against Sentiment at 6.6 and asymmetric R:R of 0.00.
The strongest dimensions are Sentiment at 6.6, Technical at 6.6, and Value at 5.0; the weakest are Momentum at 2.9, Peer rank at 3.1, and Quality at 3.6. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Cash Burn Runway Risk
Trip ifCash burn rate improves to less than 200% of quarterly revenue for 2 consecutive quarters.
- P2Quality Fails Minimum Threshold
Trip ifQuality score rises above 4.5 for 2 consecutive assessment periods.
- P3Wide Upside To Analyst TargetTripped
Trip ifAnalyst consensus take-profit target is revised below $25, cutting the implied upside to less than 40% from the current $18.12 price level.
- P4Favorable Asymmetry Blocked By Quality
Trip ifAsymmetry ratio falls below 1.5 as price appreciation narrows the gap to the $35.33 take-profit target.